Cargando…
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932040/ https://www.ncbi.nlm.nih.gov/pubmed/29720672 http://dx.doi.org/10.1038/s41598-018-25263-5 |